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Modulation of  CaV1.3b L‑type calcium 
channels by  M1 muscarinic receptors varies 
with  CaVβ subunit expression
Mandy L. Roberts‑Crowley1 and Ann R. Rittenhouse1,2* 
Abstract 
Objectives: We examined whether two G protein‑coupled receptors (GPCRs), muscarinic  M1 receptors  (M1Rs) and 
dopaminergic  D2 receptors  (D2Rs), utilize endogenously released fatty acid to inhibit L‑type  Ca
2+ channels,  CaV1.3. 
HEK‑293 cells, stably transfected with  M1Rs, were used to transiently transfect  D2Rs and  CaV1.3b with different 
 CaVβ‑subunits, allowing for whole‑cell current measurement from a pure channel population.
Results: M1R activation with Oxotremorine‑M inhibited currents from  CaV1.3b coexpressed with α2δ‑1 and a β1b, β2a, 
β3, or β4‑subunit. Surprisingly, the magnitude of inhibition was less with β2a than with other  CaVβ‑subunits. Normal‑
izing currents revealed kinetic changes after modulation with β1b, β3, or β4, but not β2a‑containing channels. We 
then examined if  D2Rs modulate  CaV1.3b when expressed with different  CaVβ‑subunits. Stimulation with quinpirole 
produced little inhibition or kinetic changes for  CaV1.3b coexpressed with β2a or β3. However, quinpirole inhibited 
N‑type  Ca2+ currents in a concentration‑dependent manner, indicating functional expression of  D2Rs. N‑current inhi‑
bition by quinpirole was voltage‑dependent and independent of phospholipase  A2  (PLA2), whereas a  PLA2 antagonist 
abolished  M1R‑mediated N‑current inhibition. These findings highlight the specific regulation of  Ca
2+ channels by dif‑
ferent GPCRs. Moreover, tissue‑specific and/or cellular localization of  CaV1.3b with different  CaVβ‑subunits could fine 
tune the response of  Ca2+ influx following GPCR activation.
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Introduction
Voltage-gated  Ca2+ channels (VGCCs) control mem-
brane excitability, gene expression, and neurotransmitter 
release [1]. Alterations in these cellular functions occur 
when GPCR-activated signal transduction cascades 
modulate VGCCs. In medium spiny neurons (MSNs) of 
the striatum, GPCRs, including  M1Rs and  D2Rs, inhibit 
VGCC activity [2, 3]. These GPCRs specifically inhibit 
 CaV1.3 L-current, decreasing the output of MSNs [3, 4] 
and may have functional consequences for motor control 
[5, 6].
Although present in MSNs,  M1R signaling has been 
characterized most thoroughly in superior cervical gan-
glion (SCG) neurons.  M1Rs couple to Gαq and phospho-
lipase C (PLC) to inhibit native L- and N-VGCC currents 
[7–9]. This signal transduction cascade, referred to as the 
slow or diffusible second messenger pathway, is char-
acterized as pertussis toxin (PTX)-insensitive, voltage-
independent, and requiring intracellular  Ca2+ to function 
[10]. Our laboratory has identified arachidonic acid (AA) 
as a critical effector in the slow pathway [9]. Exogenously 
applied AA inhibits L-current [11–13], which in SCG 
neurons most likely arises from  CaV1.3 [14]. Moreover, 
 Ca2+-dependent cytosolic phospholipase  A2  (cPLA2) 
appears critical for release of AA from phospholipids fol-
lowing  M1R activation; loss of  cPLA2 activity by pharma-
cological antagonists or gene knockout ablates L-current 
inhibition [15, 16].
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Additionally,  D2Rs inhibit L-current via a diffusible 
second messenger pathway involving phospholipase C 
(PLC),  InsP3, and calcineurin in MSNs [3]. While both 
GPCRs signal through PLC, they share another com-
monality: their activation releases AA from striatal neu-
rons [17, 18] and transfected cell lines [19, 20]. Therefore, 
 D2Rs may also inhibit L-  (CaV1.3) and N-(CaV2.2) cur-
rents via a pathway utilizing  cPLA2 to release AA. In 
the present study, we tested whether the  M1R and  D2R 
pathways converge to modulate recombinant L-VGCC 
activity.
Main text
Materials and methods
Cell culture
Human embryonic kidney cells, stably transfected with 
the M1 muscarinic receptor (HEK-M1) [a generous gift 
from Emily Liman, University of Southern California, 
originally transfected by [21] ] were propagated at 37 °C 
with 5%  CO2 in Dulbecco’s MEM (DMEM)/F12 supple-
mented with 10% FBS, 1% G418, 0.1% gentamicin, and 
1% HT supplement (Gibco Life Technologies). Cells were 
passaged when 80% confluent.
Transfection
HEK-M1 cells, grown in 12-well plates (~ 60–80% conflu-
ent), were transfected with a 1:1:1 molar ratio of  CaV1.3b 
or  CaV2.2, α2δ-1 and different  CaVβs [22], using Lipo-
fectamine PLUS (Invitrogen) according to the manufac-
turer’s instructions. Cells were co-transfected with green 
fluorescent protein (GFP) to identify transfected cells. 
Constructs for  CaV1.3b (+exon11, Δexon32, +exon42a; 
GenBank accession #AF370009),  CaV2.2 (a10, Δexon18a, 
Δexon24a, +exon31a, +exon37b, +exon46; #AF055477), 
 CaVβ3 (#M88751) and α2δ-1 (#AF286488) were pro-
vided by Diane Lipscombe (Brown University).  CaVβ1b 
(#X61394),  CaVβ2a (#M80545), and  CaVβ4 (#L02315) con-
structs were provided by Edward Perez-Reyes (University 
of Virginia). The  D4.4R (#AF1199329) construct was pro-
vided by Hubert H. M. Van Tol (University of Toronto). 
 D2R cDNA (#NM_000795) was obtained from the UMR 
cDNA Resource Center (https ://www.cdna.org). Per well, 
a total of 0.5 μg of DNA (of which GFP cDNA was less 
than 10%) was used following the methods of Roberts-
Crowley and Rittenhouse (2009) [13].
Electrophysiology
Whole-cell currents were recorded following the meth-
ods of Liu et  al. [11]. High resistance seals were estab-
lished in  Mg2+ Tyrode’s (in mM): 5  MgCl2, 145 NaCl, 
5.4 KCl, and 10 HEPES, brought to pH 7.50 with NaOH. 
Once a seal was established and the membrane ruptured, 
the Tyrode’s solution was exchanged for external bath 
solution (in mM): 125 NMG-aspartate, 20 Ba-acetate, 
10 HEPES, brought to pH 7.50 with CsOH. Only cells 
with ≥ 0.2 nA of current were used. Data were acquired 
using Signal 2.14 software (CED) and stored for later 
analysis on a personal computer. Linear leak and capaci-
tive currents were subtracted from all traces.
Drugs
All chemicals were purchased from Sigma unless oth-
erwise noted. FPL 64176 (FPL), nimodipine (NIM), and 
oleoyloxyethyl phosphorylcholine (OPC, Calbiochem) 
were prepared as stock solutions in 100% ethanol. Quin-
pirole (quin) and Oxotremorine-M (Oxo-M, Tocris) were 
dissolved in DDW and stored as 10 mM stock solutions 
at − 70 °C. Stocks were diluted daily to the final concen-
tration by at least 1000-fold with external solution. For 
ethanol-prepared stocks, the final ethanol concentration 
was less than 0.1%.
Statistical analysis
Data are presented as the mean ± s.e.m. Data were ana-
lyzed for significance using a Student’s paired t-test for 
two means, or a one-way ANOVA followed by a Tukey 
multiple-comparison post hoc test. Statistical signifi-
cance was set at p < 0.05 or < 0.001. Analysis programs 
included Signal (CED), Excel (Microsoft), and Origin 
(OriginLab).
Results
Characterization of recombinant  CaV1.3 current as L‑type 
in HEK‑M1 cells
Whole-cell L-currents, from β3-containing L-channels, 
elicited from a holding potential of − 60  mV to a test 
potential of − 10  mV, averaged − 4699 ± 279 pA (n = 3) 
compared to − 9 ± 1 pA for HEK-M1 cells transfected 
with only accessory subunits (n = 10, P < 0.001). Lack 
of current from cells transfected without  CaV1.3b, con-
firmed that HEK-M1 cells exhibit little endogenous  Ca2+ 
current and transfection of accessory subunits does 
not upregulate endogenous  Ca2+ channels. Recombi-
nant current was confirmed as L-type by showing sen-
sitivity to the L-VGCC antagonist NIM. NIM inhibited 
β3-containing currents (Additional file 1A) in a concen-
tration-dependent manner (Additional file 1B). Currents 
were also sensitive to FPL, which enhanced current from 
β2a- and β3-containing channels and produced long-last-
ing tail currents upon repolarization (Additional file 1C, 
D). Additionally, FPL produced a slight hyperpolarizing 
voltage shift in the peak inward current and enhanced 
current amplitude at all voltages (Additional file  1E). 
Additional file  1F demonstrates that FPL enhanced the 
long-lasting tail current in a concentration-depend-
ent manner. These pharmacological and biophysical 
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properties show that transfection of HEK-M1 cells with 
 CaV1.3b and accessory subunits produce currents with 
L-type characteristics.
The  CaVβ‑subunit varies the magnitude of  CaV1.3 current 
inhibition by  M1Rs
In MSNs,  M1R stimulation inhibits L-current in  CaV1.2 
knockout animals [4]. Only  CaV1.2 and  CaV1.3 consti-
tute the L-type  CaVα1 subunits expressed in brain [23], 
implying that  M1Rs specifically inhibit  CaV1.3 current. 
Using a cell line transfected with only  CaV1.3 channels 
provides molecular proof for the identity of the inhib-
ited channel. Therefore, to determine if activation of 
 M1Rs inhibits  CaV1.3 activity, peak current amplitudes 
were measured prior to and following application of the 
 M1R agonist Oxo-M. Figure  1a compares representa-
tive current traces for  CaV1.3b coexpressed with β1b, β2a, 
β3, or β4-subunits in the absence or presence of Oxo-M. 
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Fig. 1 CaV1.3b current inhibition and kinetic changes produced by  M1R stimulation are  CaVβ‑subunit dependent. a Representative current 
traces from  CaV1.3b coexpressed with β1b, β2a, β3 or β4 before (black) or 1 min after applying 10 μM Oxo‑M (red). b Current traces from a were 
normalized to the end of the test pulse. c Summary of Oxo‑M inhibition of  CaV1.3b with different  CaVβ‑subunits. Maximal inward current amplitudes 
were measured after the onset of the test pulse using a trough seeking function (peak current). Percent of current inhibition was calculated as: 
%Iinhib= 100*(ICTL–IDRUG )∕ICTL , where  ICTL and  IDRUG  are the average maximum current amplitude of 5 traces prior to and after 1 min of application 
of test material (unless otherwise noted). d Schematic of quantification of kinetic changes. e, f Summary of kinetic changes (n = 4–6, ***P < 0.001, 
**P < 0.05) open bars, control; hatched bars, Oxo‑M. e Time to peak (TTP) was measured using a minimum seeking function in Signal within the 
test pulse duration. f Current remaining (r40) was measured from an average of five normalized current traces per condition using the equation: 
r40 = 100*Iend∕Ipeak , where r40 is the percent of the maximum inward current remaining at the end of a 40 ms test pulse;  Iend is the current 
amplitude at the end of the test pulse;  Ipeak is the maximum inward current measured during the test pulse
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After 1  min, Oxo-M significantly inhibited L-current 
by 58 ± 8% with β1b; 36 ± 12% with β2a; 66 ± 6% with β3; 
and 72 ± 10% with β4 (Fig.  1c). Oxo-M elicited kinetic 
changes that were visualized by normalizing individual 
traces to the end of the 40 ms test pulse (Fig. 1b), which 
were quantified by measuring TTP and r40 (Fig. 1d). TTP 
(Fig.  1e) and r40 (Fig.  1f ) decreased following Oxo-M 
with β1b, β3, or β4; however, no changes were detected 
with β2a (P ≥ 0.11 for TTP; P ≥ 0.40 for r40). These differ-
ences in the magnitude of current inhibition and kinetics 
suggest that the  CaVβ-subunit affects  M1R modulation of 
 CaV1.3b.
Dopamine  D2 receptors inhibit  CaV2.2 but not  CaV1.3 currents
Both  M1Rs and  D2Rs activate pathways involving G pro-
teins, PLC, and AA release (Fig.  2a). However, whether 
L-current inhibition by  D2Rs shows varied inhibition 
depending on  CaVβ-subunit expression has not been 
examined. Therefore, we coexpressed  D2Rs with  CaV1.3b, 
α2δ-1 and different  CaVβ-subunits. While Oxo-M inhib-
ited  CaV1.3b-β2a currents over time (Fig.  2b), quin, a 
 D2R agonist, had no effect on current amplitude (Fig. 2c) 
or kinetics (Fig.  2c inset, g). Since  CaV1.3b-β2a current 
shows less inhibition and no kinetic changes with Oxo-
M, we tested whether  CaV1.3b-β3 current was sensitive 
to modulation by quin. Figure  2d shows a time course 
of  CaV1.3b-β3 current inhibition by Oxo-M whereas the 
time course with quin (Fig.  2e) shows no inhibition or 
kinetic change (Fig.  2e inset, g). Several concentrations 
of quin were tested but did not inhibit L-current to the 
same extent as Oxo-M (Fig. 2f ).  D2Rs appeared to desen-
sitize with 10 μM quin. Application of quin for 1 min to 
cells co-transfected with the  D2R-like family member, 
 D4.4R, inhibited L-current by 8.5 ± 2.5% and did not pro-
duce changes in TTP or r40 (Additional file 2).
To confirm that lack of L-current inhibition was not 
due to poor expression of  D2Rs, we repeated the experi-
ment but substituted  CaV2.2 for  CaV1.3b to serve as a 
positive control since activated  D2Rs also inhibit  CaV2.2 
[24–26]. Quin inhibited  CaV2.2 by 45 ± 7% after 30 s and 
48 ± 4% after 1 min (Fig. 3a). Inhibition occurred specifi-
cally by activating transfected  D2Rs because cells trans-
fected without  D2Rs showed no response to quin (Fig. 3a, 
n = 3). Moreover, N-current inhibition by quin occurred 
in a concentration-dependent manner (Fig. 3b, n = 3–5). 
Compared to lower concentrations, 10 μM quin resulted 
in less inhibition; inhibited current did not recover upon 
wash, suggesting this concentration causes receptor 
desensitization (data not shown). Thus, our findings indi-
cate that transfected  D2Rs functionally express in HEK-
M1 cells to modulate  CaV2.2, but not  CaV1.3b VGCC 
activity.
M1R and  D2R pathways use different signaling mechanisms 
to inhibit N‑current
To compare  D2Rs and  M1Rs signaling pathways on 
 CaV2.2 current, we first confirmed that activation of 
the stably transfected  M1Rs could suppress N-current. 
Indeed, Oxo-M inhibited currents from β3-containing 
channels by 70 ± 5% after 30  s (Fig.  3c). When incu-
bated with the  PLA2 antagonist OPC, cells showed less 
N-current inhibition by Oxo-M, 14 ± 8% inhibition after 
30 s (Fig. 3c). In contrast, low concentrations of quin still 
suppressed N-current in the presence of OPC (Fig.  3d). 
Inhibition was relieved by pre-pulse facilitation (Fig. 3e, 
g, h) and occurred in the presence of BSA, which acts as 
a scavenger of free AA (Fig. 3f–h), suggesting that quin 
mediates membrane-delimited inhibition of N-current. 
These findings suggest that  M1Rs and  D2Rs do not share a 
common pathway leading to N-current inhibition.
Discussion
Previously, the  CaV1.3b splice variant of L-VGCCs, found 
in MSNs, had not been specifically tested for modula-
tion by GPCRs. Here, using HEK-M1 cells, we present 
the novel finding that  M1R stimulation inhibits  CaV1.3b 
L-current with the accessory  CaVβ-subunit determining 
the magnitude of inhibition. In contrast, stimulation of 
transfected  D2Rs with quin does not recapitulate L-cur-
rent inhibition observed in MSNs [3]. Pharmacological 
sensitivity to both FPL and NIM confirmed that  CaV1.3b 
expressed in HEK-M1 cells behaves similarly to other 
recombinant  CaV1.3 VGCCs [22, 27].
We also report that N-current modulation by the  D2R 
short splice variant appears similar to membrane-delim-
ited inhibition by the  D2R long form [24]. In this form of 
modulation, when G proteins are activated, Gβγ directly 
binds to and inhibits  CaV2.2 which can be reversed by 
strong prepulses [10, 28]. Indeed,  D2R-mediated inhibi-
tion of  CaV2.2 was independent of  PLA2, whereas block-
ers of  PLA2 abolished inhibition by  M1Rs. Thus, the 
membrane-delimited pathway may be at least partially 
responsible for the inhibition of  CaV2.2 by  D2Rs in MSNs 
[25].
In our experiments, the short splice variant of  CaV1.3 
 (CaV1.3b) was unaffected by activation of  D2Rs, expressed 
in HEK-293 cells, similar to a previous report on  CaV1.3a, 
which has a longer C-terminus [24]. Since neither 
 D2R-long inhibited  CaV1.3a [24], nor  D2R-short inhibited 
 CaV1.3b (Fig. 2f ), one possibility is that another channel/
receptor combination occurs in  vivo; however,  D2R-long 
and short equally couple to  Gi proteins [29]. On the other 
hand,  CaV1.3a binds a scaffolding protein found in the 
postsynaptic density of synapses known as Shank [30]. 
In MSNs,  CaV1.3a requires an association with Shank for 
current inhibition by  D2Rs [4]. Although lack of the longer 
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 CaV1.3 C-terminus may explain the absence of channel 
modulation by  D2Rs in our studies, we found that Oxo-M 
inhibits  CaV1.3b currents, showing that this short splice 
variant of  CaV1.3 can be modulated by a  GqPCR. There-
fore, a missing intermediary protein vital for  D2R modu-
lation of  CaV1.3b may underlie the lack of inhibition 
reported here, or  D2Rs may not modulate  CaV1.3b.
Conclusions
These findings highlight the specific regulation of  Ca2+ 
channels in a  CaVβ-subunit dependent manner by dif-
ferent neurotransmitters. While  M1R and  D2R pathways 
contain similar signaling molecules and share a com-
mon functional output of inhibiting  Ca2+ channels, dif-
ferences between the two cascades exist. Expression 
and localization of  CaV1.3b associated with different 
 CaVβ-subunits in a tissue or cell may dictate how  Ca2+ 
influx is modulated by nearby GPCRs, ultimately affect-
ing  Ca2+-dependent processes.
Limitations
Further experiments are needed to determine the differ-
ences in signaling between successful  CaV1.3b inhibition 
by  M1Rs versus none with  D2Rs.
Additional files
Additional file 1. Pharmacological characterization of  CaV1.3b L‑current. 
HEK‑M1 cells were washed with DMEM and the DNA mixture of  CaV1.3b, 
α2δ‑1, a β3‑subunit and GFP was added and incubated for 1 h at 37 °C in 
a 5%  CO2 incubator. Supplemented media, without antibiotics, was then 
returned to the cells to bring the volume up to 1 ml (normal medium 
volume). After 2 h, cells were washed with supplemented media and 
washed a final time 2 h later. 10 mM  MgSO4 was added to the medium 
to block basal activity of  CaV1.3b, which helped minimize excitotoxic‑
ity of transfected cells. Cells were transferred 24–72 h post‑transfection 
using 2 mM EDTA in 1X PBS, to poly‑l‑lysine‑coated coverslips. Recording 
began 1 h after transfer to coverslips. A Individual traces of  CaV1.3b‑β3 
current before (CTL) and after exposure to 0.3 µM NIM. B Concentra‑
tion–response curve of L‑current inhibition to NIM (n = 4–8). C  CaV1.3b‑β2a 
currents before and after exposure to FPL (1 µM). Cells were stepped to a 
test potential of − 10 mV from a holding potential of − 90 mV followed 
by repolarization to − 90 or − 50 mV. Control (CTL) currents from β2a‑
containing L‑VGCCs show little to no inactivation as observed previously 
[31]. D  CaV1.3b‑β3 currents before and after FPL. Cells were stepped to a 
test potential of − 10 mV from a holding potential of − 60 mV followed 
by repolarization to − 60 mV. Following FPL, both β2a‑ and β3‑containing 
channels exhibited slower activation and deactivation kinetics, hallmarks 
of agonist action on L‑current [32]. E FPL enhancement of the  CaV1.3b‑β2a 
current–voltage plot from a holding potential of − 90 mV (CTL, filled cir‑
cles; FPL, open circles, n = 3, *P < 0.05). F Concentration–response curve of 
 CaV1.3b‑β3 tail current enhancement to FPL (n = 4–8). Currents inhibited 
by NIM and enhanced by FPL fully recovered by washing with bath solu‑
tion (data not shown).
Additional file 2.  D4.4Rs do not inhibit recombinant L‑current. A Summary 
bar graph of  CaV1.3b‑β3 current inhibition by 0.5 μM quin (n = 5). B & C 
Summary bar graphs of TTP and r40 kinetic analysis.
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